Styx Biotechnologies, Inc.
PrivateLast Round
Corporate Funding
Sep 1, 2026
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Styx Biotechnologies, Inc. is a biotechnology company that develops next-generation antibody-drug conjugates (ADCs) and targeted therapeutics for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Styx Biotechnologies, Inc. Comparables
Compare Styx Biotechnologies, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ZoeNCure Therapeutics | 58% |
For institutional investors. Book with your work email.
Styx Biotechnologies, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Sep 1, 2026 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2026
Raised funding from ZoeNCure Therapeutics.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 28, 2026
Styx Biotechnologies Inc. is developing antibody-drug conjugates, including lead candidate STX-ADC02 for hepatocellular carcinoma, which targets the GPC3 protein and uses two cancer-killing drug payloads.
- is_developingOct 28, 2026
Styx Biotechnologies Inc. is developing its lead drug candidate, STX-ADC02, as an antibody-drug conjugate targeting GPC3 in hepatocellular carcinoma, with ZoeNCure providing development funding and supporting early clinical studies in India.
- partners_withSep 1, 2026
Styx Biotechnologies Inc. and ZoeNCure partner under a strategic agreement to accelerate selected ADC programs toward first-in-human clinical studies, with ZoeNCure providing development capital and clinical infrastructure while Styx Biotechnologies Inc. preserves global development rights in California on Sep 1st '26.
For institutional investors. Book with your work email.
Styx Biotechnologies, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Styx Biotechnologies, Inc.'s valuation, stock price, and market status.
Is Styx Biotechnologies, Inc. a public or private company?
Styx Biotechnologies, Inc. is a private company.
What is the current stock price of Styx Biotechnologies, Inc.?
Styx Biotechnologies, Inc. is a private company, so its shares have no public market price. Caplight tracks Styx Biotechnologies, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Styx Biotechnologies, Inc. worth (valuation)?
Valuation information for Styx Biotechnologies, Inc. is not publicly available.
Can I buy Styx Biotechnologies, Inc. stock?
Styx Biotechnologies, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Styx Biotechnologies, Inc.'s last funding round?
Styx Biotechnologies, Inc.'s most recent funding round was Corporate Funding on September 1, 2026.
Who are the main investors in Styx Biotechnologies, Inc.?
Investor information for Styx Biotechnologies, Inc. is not publicly disclosed.
Will Styx Biotechnologies, Inc. IPO soon?
No public IPO plans have been announced for Styx Biotechnologies, Inc..
How can I track Styx Biotechnologies, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Styx Biotechnologies, Inc.'s shares on secondary markets.